Form 4: Karyopharm Officer Reports Stock Transactions

Karyopharm Therapeutics' Chief Accounting Officer, Kristin Abate, reported the acquisition of shares from PSU vesting and a subsequent sale for tax obligations.

Summary

• Kristin Abate, Chief Accounting Officer of Karyopharm Therapeutics Inc. (KPTI), reported changes in her beneficial ownership of common stock.
• On September 12, 2025, Abate acquired 46 shares of common stock upon the vesting of performance-based restricted stock units (PSUs).
• These PSUs were granted in February 2023 and earned based on the achievement of a clinical milestone for complete enrollment in the Company's Phase 3 SENTRY trial, as certified by the Compensation Committee.
• Following this acquisition, Abate beneficially owned 10,431 shares.
• On September 15, 2025, Abate sold 23 shares of common stock at a price of $6.43 per share.
• This sale was a non-discretionary broker-assisted transaction executed under a Rule 10b5-1 plan adopted on May 27, 2021, to satisfy tax withholding liabilities incurred upon the PSU vesting.
• After the sale, Abate's beneficial ownership stands at 10,408 shares.
• Her total beneficial ownership also includes 922 shares acquired through the Karyopharm Therapeutics Inc. Amended & Restated 2013 Employee Stock Purchase Plan on April 30, 2025.

Sentiment

Score: 5

Explanation: The filing details routine insider transactions related to compensation (PSU vesting and subsequent tax-related sale). The achievement of a clinical milestone for PSU vesting is a positive operational indicator, but the overall transaction is neutral in terms of discretionary insider sentiment.

Positives

• The vesting of performance-based restricted stock units (PSUs) indicates the achievement of a clinical milestone, specifically complete enrollment in the Company's Phase 3 SENTRY trial.

Negatives

• The sale of 23 shares, even for tax purposes, represents a reduction in the reporting person's direct beneficial ownership.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may note the achievement of a clinical milestone (complete enrollment in Phase 3 SENTRY trial) which led to the PSU vesting, indicating progress in the company's drug development pipeline.

Key Dates

Recommendation

This Form 4 details routine insider transactions related to compensation (PSU vesting and subsequent tax-related sale). It does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. The meeting of a clinical milestone for PSU vesting is a positive operational indicator, but the transaction itself is not a discretionary buy or sell decision by management, thus maintaining a 'hold' stance.

Keywords

Karyopharm Therapeutics, KPTI, insider transaction, Form 4, stock transaction, PSU, restricted stock units, Chief Accounting Officer, Kristin Abate, stock sale, tax withholding, Rule 10b5-1 plan